Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Characterizing the role of the SWI/SNF Complex in Oncolytic Virotherapy.
EF 2018-19
Résumé
Despite extensive research and efforts, cancer remains the leading cause of death among Canadians. Therapeutic advances have led to the development of immunotherapies; treatments that utilize the patient’s immune system to help target and eliminate tumors. One such treatment is oncolytic virotherapy, which uses engineered oncolytic or “cancer-killing” viruses (OVs) to specifically infect and kill cancer cells. These OVs subsequently activate the immune system to stimulate durable anti-tumor responses. Despite strong and promising anti-tumor responses by OV in certain cancer patients, tumor diversity presents as a significant hurdle to the development of widespread cures. The SWItch/Sucrose Non-Fermentable (SWI/SWF) complex is a complex that regulates gene transcription thereby controlling numerous biological processes. Previous work in our lab has shown that functional loss of various subunits of the SWI/SNF complex leads to increased viral sensitivity and cancer cell killing of multiple OV platforms in otherwise resistant cancer cell lines. The goal of this project is to engineer an OV that is specifically equipped to target and inactivate components of the SWI/SNF complex. This should improve the infectability and killing of cancer cells, sensitizing tumors to immunotherapy and leading to durable cures. The project will also elucidate the mechanisms by which complex disruption increases tumor sensitivity to virus and assess the SWI/SNF complex status as a potential predictive marker for OV treatment response. This work will generate a novel OV candidate and has the potential to identify a biomarker predictive of tumor response to OV therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406269
Name
Brown Emily E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the role of the SWI/SNF Complex in Oncolytic Virotherapy.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Biology; Cancer Detection; Immunotherapy; Oncolytic Viruses; Swi/Snf Complex
Abstract
Despite extensive research and efforts, cancer remains the leading cause of death among Canadians. Therapeutic advances have led to the development of immunotherapies; treatments that utilize the patient’s immune system to help target and eliminate tumors. One such treatment is oncolytic virotherapy, which uses engineered oncolytic or “cancer-killing” viruses (OVs) to specifically infect and kill cancer cells. These OVs subsequently activate the immune system to stimulate durable anti-tumor responses. Despite strong and promising anti-tumor responses by OV in certain cancer patients, tumor diversity presents as a significant hurdle to the development of widespread cures. The SWItch/Sucrose Non-Fermentable (SWI/SWF) complex is a complex that regulates gene transcription thereby controlling numerous biological processes. Previous work in our lab has shown that functional loss of various subunits of the SWI/SNF complex leads to increased viral sensitivity and cancer cell killing of multiple OV platforms in otherwise resistant cancer cell lines. The goal of this project is to engineer an OV that is specifically equipped to target and inactivate components of the SWI/SNF complex. This should improve the infectability and killing of cancer cells, sensitizing tumors to immunotherapy and leading to durable cures. The project will also elucidate the mechanisms by which complex disruption increases tumor sensitivity to virus and assess the SWI/SNF complex status as a potential predictive marker for OV treatment response. This work will generate a novel OV candidate and has the potential to identify a biomarker predictive of tumor response to OV therapy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brown, Emily E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~